Twist Bioscience Corporation Q1 2026 Earnings Recap

TWST Q1 2026 February 2, 2026

Twist Bioscience reported robust performance in Q1 of fiscal 2026, achieving its twelfth consecutive quarter of revenue growth with a 24% CAGR over the last three years, while significantly expanding its addressable market.

Earnings Per Share Miss

$-0.50 vs $-0.48 est.

-4.2% surprise

Revenue Beat

103698000 vs 101882900 est.

+1.8% surprise

Market Reaction

1-Day +13.98%

5-Day +19.89%

30-Day +20.72%

Key Takeaways

Revenue growth of 24% CAGR over the past three years, reflecting strong operational momentum.
Serviceable market expanded from $2 billion in 2020 to approximately $7 billion, with potential to exceed $12 billion by 2030.
Continued investment in AI-enabled therapeutics discovery led to over $25 million in orders booked, showcasing market leadership initiatives.
New product launches utilizing the semiconductor-based DNA synthesis platform are enhancing competitive positioning without increasing operational risk.
Strategic focus on expanding customer relationships and workflows in diagnostics and biopharma sectors is expected to drive sustained growth.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit TWST on AllInvestView.

Previous Q4 2025